The next 12-18 months will be fascinating for both stocks. MSB seeking approval for Revascor and Rem-L in blockbuster indications. Literally billions in sales could be just around the corner. CYP getting results for:
HR-aGvHD: Definitely not a blockbuster, but worth US$100M in upfront and milestone payments alone based on the Ruxolitinib deal. Knee OA: Blockbuster, may get approval in Aus but will probably need another trial in the US+EU. What do you pay in upfront and milestones for a condition that half a billion people deal with every day?
A big 18 months for MSC's.
CYP Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)